CandlesenseCandlesense
News/Companies/NXTC

NXTC News

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NXTC

(NASDAQ:NXTC) BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference in New York City on Monday, September 8th, at 4:00 pm ET.

September 4, 2025Investor Relations
Read more →

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

NXTC

BELTSVILLE, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported second quarter 2025 financial results.

August 7, 2025Earnings
Read more →

NextCure And LigaChemBio Announces They Will Present Trial In Progress Poster For LNCB74, A B7-H4 Targeted Antibody-Drug Conjugate, As Monotherapy In Participants With Advanced Solid Tumors At American Society of Clinical Oncology 2025

NXTC

May 29, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $3 Price Target

NXTC

March 17, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on NextCure, Lowers Price Target to $3

NXTC

March 7, 2025
Read more →

NextCure FY 2024 GAAP EPS $(1.99) Misses $(1.92) Estimate

NXTC

March 6, 2025
Read more →

NextCure Doses First Patient Dosed In Phase 1 Study Of LNCB74 (For Treating Multiple Cancers

NXTC

January 10, 2025
Read more →

NextCure Highlights Presentation Of Data Demonstrating That NC605 Resulted In Enhanced Generation Of Quality Bone With Better Mechanical Properties

NXTC

November 19, 2024
Read more →

NextCure Reports Preclinical Data For LNCB74 And Additional Clinical Biomarker Data For NC410 Combo At Society For Immunotherapy Of Cancer Annual Meeting

NXTC

November 5, 2024
Read more →